We’ve put some small files called cookies on your device to make our site work.
We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We’ll use a cookie to save your choice. You can read more about our cookies before you choose.
Change my preferences
I'm OK with analytics cookies
Baricitinib is recommended to be available as a treatment option through routine commissioning for adults and children 2 years and over with monogenic interferonopathies within the criteria set out in this document.